To rule out differences in the response to IFN-β we will include both healthy volunteers as the first population within the clinical testing being exposed to the RIG-I ligand as well as patients with relapsing-remitting multiple sclerosis as patients meant to be treated with the RIG-I ligand later in development. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.